[1]CurrentPatentAssignee:WUHANHITECKBIOLOGICALPHARMACOLTD-CN106543225,2017,ALocationinpatent:Paragraph0024
Title: Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601
Title: [New approved drugs for osteoporosis in Japan].
Journal: Clinical calcium 20120601
Title: Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.
Journal: Toxicology and applied pharmacology 20120315
Title: Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Journal: Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20111201
Title: Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors.
Journal: European journal of medicinal chemistry 20111001
Title: A serendipitous phosphonocarboxylate complex of boron: when vessel becomes reagent.
Journal: Chemical communications (Cambridge, England) 20110614
Title: [Minodronic acid- its clinical efficacy and prospects for once-a-month dosing regimen].
Journal: Clinical calcium 20110101
Title: Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway.
Journal: Clinical & experimental metastasis 20101001
Title: Minodronate for the treatment of osteoporosis.
Journal: Drugs of today (Barcelona, Spain : 1998) 20100101
Title: [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090901
Title: Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090801
Title: A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Journal: Bone 20090601
Title: [Drugs under development for osteoporosis ].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20090501
Title: [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
Journal: Clinical calcium 20090101
Title: [New development in bisphosphonate treatment. Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis].
Journal: Clinical calcium 20090101
Title: New bisphosphonates and trends in drug therapy for osteoporosis: preface.
Journal: Clinical calcium 20090101
Title: Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.
Journal: Bone 20081101
Title: Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.
Journal: Bone 20081101
Title: Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.
Journal: European journal of pharmacology 20080728
Title: Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Journal: Cancer chemotherapy and pharmacology 20080601
Title: Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
Journal: Bioorganic & medicinal chemistry letters 20080501
Title: Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells.
Journal: Cancer science 20080101
Title: [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Journal: Nihon rinsho. Japanese journal of clinical medicine 20071128
Title: Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate.
Journal: Cancer letters 20070808
Title: [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Journal: Clinical calcium 20070101
Title: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.
Journal: BMC cancer 20070101
Title: Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.
Journal: Modern rheumatology 20070101
Title: A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.
Journal: British journal of cancer 20061120
Title: Minodronate suppresses prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts.
Journal: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20060301
Title: Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.
Journal: Medical hypotheses 20060101
Title: Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050915
Title: Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Journal: Biochemical and biophysical research communications 20050304
Title: A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20050115
Title: [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Journal: Clinical calcium 20050101
Title: Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
Journal: International journal of tissue reactions 20050101
Title: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.
Journal: The American journal of pathology 20041201
Title: Effects of YM529, a novel minodronic acid, on adjuvant arthritis in rats.
Journal: Clinical and experimental rheumatology 20040101
Title: Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20031101
Title: A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK.
Journal: Life sciences 20031010
Title: Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
Journal: Cellular signalling 20030701
Title: Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis.
Journal: Arthritis and rheumatism 20030601
Title: A new stressed test to predict the foreign matter formation of minodronic acid in solution.
Journal: International journal of pharmaceutics 20030130
Title: Failure of stability prediction for minodronic acid injectable by accelerated stability testing.
Journal: International journal of pharmaceutics 20020708
Title: Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
Journal: International journal of hematology 20020601
Title: Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy.
Journal: The Journal of endocrinology 20011101
Title: Stabilization of minodronic acid in aqueous solution for parenteral formulation.
Journal: International journal of pharmaceutics 20010703
Title: A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Journal: Leukemia research 20010101
